<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><?properties manuscript?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-journal-id">9918230896206676</journal-id><journal-id journal-id-type="pubmed-jr-id">50826</journal-id><journal-id journal-id-type="nlm-ta">Ophthalmol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Ophthalmol Sci</journal-id><journal-title-group><journal-title>Ophthalmology science</journal-title></journal-title-group><issn pub-type="epub">2666-9145</issn></journal-meta><article-meta><article-id pub-id-type="pmid">36051248</article-id><article-id pub-id-type="pmc">PMC9432820</article-id><article-id pub-id-type="doi">10.1016/j.xops.2021.100084</article-id><article-id pub-id-type="manuscript">NIHMS1829272</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Rescue of the Congenital Hereditary Endothelial Dystrophy Mouse Model by Adeno-Associated Viruse&#x02013;Mediated <italic toggle="yes">Slc4a11</italic> Replacement</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shyam</surname><given-names>Rajalekshmy</given-names></name><degrees>PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Ogando</surname><given-names>Diego G.</given-names></name><degrees>PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Edward T.</given-names></name><degrees>BS</degrees></contrib><contrib contrib-type="author"><name><surname>Murugan</surname><given-names>Subashree</given-names></name><degrees>BOptom</degrees></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Moonjung</given-names></name><degrees>PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Bonanno</surname><given-names>Joseph A.</given-names></name><degrees>OD, PhD</degrees></contrib><aff id="A1">Vision Science Program, School of Optometry, Indiana University Bloomington, Bloomington, Indiana.</aff></contrib-group><author-notes><fn fn-type="con" id="FN1"><p id="P1">Author Contributions:</p><p id="P2">Conception and design: Shyam, Ogando, Bonanno</p><p id="P3">Data collection: Shyam, Ogando, Kim, Murugan, Choi</p><p id="P4">Analysis and interpretation: Shyam, Ogando, Kim, Murugan, Bonanno</p><p id="P5">Obtained funding: Shyam, Bonanno; Study was performed as part of the authors&#x02019; regular employment duties. No additional funding was provided.</p><p id="P6">Overall responsibility: Shyam, Ogando, Kim, Murugan, Choi, Bonanno</p></fn><corresp id="CR1">Correspondence: Rajalekshmy Shyam, PhD, 800 E. Atwater Avenue, Indiana University School of Optometry, Bloomington, IN 47402, <email>rashyam@iu.edu</email>.</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>19</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>23</day><month>11</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>8</month><year>2022</year></pub-date><volume>2</volume><issue>1</issue><elocation-id>100084</elocation-id><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p></license></permissions><abstract id="ABS1"><sec id="S1"><title>Purpose:</title><p id="P7">Congenital hereditary endothelial dystrophy (CHED) is a rare condition that manifests at an early age showing corneal edema, increased oxidative stress, mitochondrial dysfunction, and eventually apoptosis of the endothelium due to loss of function of the membrane transport protein SLC4A11. This project tested whether replacing <italic toggle="yes">Slc4a11</italic> into the <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> CHED mouse model can reverse the disease-associated phenotypes.</p></sec><sec id="S2"><title>Design:</title><p id="P8">Experimental study.</p></sec><sec id="S3"><title>Participants:</title><p id="P9">Five-week-old or 11-week-old <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> mice. Age- and gender-matched <italic toggle="yes">Slc4a11</italic><sup>+/+</sup> animals were used as controls. A total of 124 animals (62 female, and 62 male) were used in this study. Fifty-three animals of the genotype <italic toggle="yes">Slc4a11</italic><sup>+/+</sup> were used as age- and gender-matched noninjected controls. Seventy-one <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> mice were administered anterior chamber injections of adeno-associated virus (AAV).</p></sec><sec id="S4"><title>Methods:</title><p id="P10">Anterior chambers of young (5 weeks old) or older (11 weeks old) <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> mice were injected once with adeno-associated virus serotype 9 (AAV9) mouse <italic toggle="yes">Slc4a11</italic> or AAV9-Null vectors. Corneal thickness was measured using OCT. End point analysis included corneal endothelial cell density, mitochondrial oxidative stress, and corneal lactate concentration.</p></sec><sec id="S5"><title>Main Outcome Measures:</title><p id="P11">Corneal thickness, endothelial cell loss, lactate levels, and mitochondrial oxidative stress.</p></sec><sec id="S6"><title>Results:</title><p id="P12">In the young animals, AAV9-<italic toggle="yes">Slc4a11</italic> reversed corneal edema, endothelial cell loss, mitochondrial oxidative stress, lactate transporter expression, and corneal lactate concentration to the levels observed in wild-type animals. In the older animals, gene replacement did not reverse the phenotype but prevented progression.</p></sec><sec id="S7"><title>Conclusions:</title><p id="P13">Functional rescue of CHED phenotypes in the <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> mouse is possible; however, early intervention is critical.</p></sec></abstract><kwd-group><kwd>Adeno-associated virus</kwd><kwd>Congenital hereditary endothelial dystrophy</kwd><kwd>Endothelial dystrophy</kwd><kwd>Gene therapy</kwd></kwd-group></article-meta></front><body><p id="P14">The corneal endothelium is a single layer of nonproliferating cells that line the posterior side of the cornea.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> These cells maintain corneal transparency through an active pump mechanism that moves water linked to lactate transport across the endothelium from the stroma into the aqueous humor, thereby requiring an intact osmotic barrier.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> Congenital hereditary endothelial dystrophy (CHED) is a rare recessive condition that affects 3 of 100000 newborns each year,<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup> leading to bilateral corneal edema and clouding.<sup><xref rid="R4" ref-type="bibr">4</xref>&#x02013;<xref rid="R7" ref-type="bibr">7</xref></sup> Mutations in <italic toggle="yes">Slc4a11</italic>, which codes for a plasma membrane H<sup>+</sup> transporter and an ammonia sensitive mitochondrial uncoupler,<sup><xref rid="R6" ref-type="bibr">6</xref></sup> lead to CHED.<sup><xref rid="R4" ref-type="bibr">4</xref></sup>
<italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup>(knockout [KO]) mice recapitulate the progressive corneal edema, endothelial cell loss, and corneal opacity, seen in the disease phenotype<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> along with a loss of lactate transporters and accumulation of stromal lactate.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> The only treatment available for CHED is corneal transplantation.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R11" ref-type="bibr">11</xref></sup> This invasive procedure also presents challenges because of the scarcity of donor tissue, graft rejection, and the need for prolonged postsurgical management.<sup><xref rid="R12" ref-type="bibr">12</xref>&#x02013;<xref rid="R14" ref-type="bibr">14</xref></sup></p><p id="P15">A potential treatment avenue not explored in CHED and other corneal endothelial dystrophies is gene therapy. This method has had some success in retinal diseases and glaucoma.<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup> Recently, adenovirus-mediated CRISPR/Cas9 knockdown of mutant Collagen 8a2 showed functional rescue of disease phenotype associated with early-onset Fuchs&#x02019; endothelial corneal dystrophy.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> In the current study, we asked if gene therapy can reverse the disease-associated phenotype in CHED. Anterior chamber injection of adeno-associated virus serotype 9 (AAV9) with hemagglutinin (HA) tagged mouse <italic toggle="yes">Slc4a11</italic> into <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> mice rescued the major disease phenotype, including corneal edema, stromal [lactate], and corneal endothelial cell death. Also, we show that time of intervention is crucial for altering disease progression. Delivery of AAV9-<italic toggle="yes">HA</italic>-<italic toggle="yes">Slc4a11</italic> in young mice produced some reversal of the disease, whereas in the older animals, gene replacement did not reverse the disease course but prevented progression.</p><sec id="S8"><title>Methods</title><sec id="S9"><title>Adeno-Associated Virus</title><p id="P16">Adeno-associated virus serotype 9-CAG-<italic toggle="yes">HA-Slc4a11</italic> delivered mouse <italic toggle="yes">Slc4a11</italic> cDNA with HA-tag at the N-terminus under the control of chicken &#x003b2;-actin (CAG) promoter via anterior chamber injections. The AAV9-CAG-null, which contained AAV9 capsid, CAG promoter but no transgene, was used as negative control. Both these vectors were custom produced by Vector Biolabs. The AAV9-CAG-green fluorescent protein (GFP) (#37825) was purchased from Addgene.</p></sec><sec id="S10"><title>Animal Housing, Maintenance, and Anterior Chamber Injections</title><p id="P17"><italic toggle="yes">Slc4a11</italic><sup>+/+</sup> (wild-type [WT]) and <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> mice were housed and maintained in pathogen-free conditions. All animal experiments were conducted in accordance with institutional guidelines and the current regulations of the National Institutes of Health, the US Department of Health and Human Services, the US Department of Agriculture, and the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. <italic toggle="yes">Slc4a11</italic> KO mice were created with a targeted deletion of exons 9&#x02013;13 of the mouse <italic toggle="yes">Slc4a11</italic> gene. These animals are in C57BL6 background and were a gift from Professor Eranga Vithana (Singapore National Eye Center).</p><p id="P18">Mice were anesthetized using intraperitoneal injections of ketamine, 100 mg/kg, and xylazine, 10 mg/kg. Eyes were dilated with phenylephrine hydrochloride solution (#847287, Paragon Bio Teck) and anesthetized using Proparacaine (Bausch &#x00026; Lomb). With the use of a 34-gauge needle attached to a micromanipulator (#M3301-M3-R, WPI Instruments), anterior chamber injection was conducted with the aid of microinjection syringe pump (#MICRO2T, WPI Instruments). A range of adeno-associated virus (AAV) doses from 9 &#x000d7; 10<sup>8</sup> GC/&#x003bc;l to 1 &#x000d7; 10<sup>12</sup> GC/&#x003bc;l were previously shown to effectively transduce mouse corneal endothelium.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> Therefore, we chose to inject 0.5 &#x003bc;l to 0.8 &#x003bc;l of the solution containing diluted virus (~1.0 &#x000d7; 10<sup>12</sup> GC/&#x003bc;l) and 0.1% fluorescein, to aid visualization, once into the anterior chamber of the mouse eye. One eye was injected and the other was not injected in all experiments. For negative controls, 11-week-old <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals were injected in 1 eye with 0.5&#x02013;0.8 &#x003bc;l AAV9-CAG-Null virus (0.9*10<sup>12</sup> GC/&#x003bc;l). The AAV9 serotype transduction efficiency into the corneal endothelium was determined by the injection of 0.5 &#x003bc;l AAV9-GFP (3.5 &#x000d7; 10<sup>9</sup> Viral Genome) into the anterior chamber of 11-week-old <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals. A total of 124 animals (62 female and 62 male) were used in this study. Fifty-three animals of the genotype <italic toggle="yes">Slc4a11</italic><sup>+/+</sup> were used as age- and gender-matched noninjected controls. Seventy-one <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> mice were subjected to anterior chamber injections of AAV.</p><p id="P19">Young animals were injected at 5 weeks of age and euthanized at 9 weeks of age. Older animals were injected at 11 weeks of age and euthanized at 15 weeks of age.</p></sec><sec id="S11"><title>Slit-Lamp Microscopy</title><p id="P20">Anterior flare assessments were conducted using slit-lamp microscopy on 11-week-old <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals injected with AAV-GFP. The slit-lamp user was blinded to the experimental conditions. Two male animals and 1 female animal (N = 3) were used.</p></sec><sec id="S12"><title>Immunohistochemistry</title><p id="P21">Corneas were dissected and fixed in 4% paraformaldehyde for 10 minutes at room temperature. After permeabilizing the samples using 0.5% TritonX-100 and blocking in 5% donkey serum (#017&#x02013;000-121, Jackson Immunologicals), primary antibody incubation of zonula occludens 1 (ZO-1) (#33&#x02013;9100, Thermo Fisher Scientific, 1:100) or GFP (#2555, Cell Signaling Technologies) was carried out overnight at 4&#x000b0;C in the blocking buffer. Corneas were then washed in phosphate-buffered saline (PBS) and incubated in secondary antibodies for 1 hour at room temperature. Hoescht dye (1 &#x003bc;m, # H3570, Thermo Fisher Scientific) was added to label the nuclei, and the tissues were mounted using Prolong Gold Anti-fade reagent (#P36934, Thermo Fisher Scientific). F-actin staining was conducted using Alexa Fluor 488 Phallodin (#A12379, Thermo Fisher Scientific) following manufacturer&#x02019;s instructions and examined by Zeiss LSM 800 confocal microscope (Zeiss). Fluorescence intensity for phalloidin staining and cell area measurements were performed as described previously.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> Two female animals and 1 male animal per group per staining condition were used. Six animals were used for phalloidin staining, and 6 animals were used for ZO-1 staining.</p></sec><sec id="S13"><title>Wes Immunoassay</title><p id="P22">Corneas were dissected and the endothelial cell layer was removed by peeling Descemet&#x02019;s membrane with jeweler&#x02019;s forceps. Protein lysates from corneal endothelial layers were extracted using RIPA lysis buffer (20188, Millipore Sigma) containing protease and phosphatase inhibitors. Protein lysates (1&#x02013;3 &#x003bc;g) were loaded into a 12&#x02013;230 kDa separation module kit and analyzed using the Protein Simple Wes System (Protein Simple). Wes data were obtained as virtual blots in which the molecular weight and signal intensity along with electropherograms were presented. Antibodies and dilutions are as follows: monocarboxylate transporter (MCT)1 (Santa Cruz Biotechnologies, #sc365501, 1:10), MCT2 (Santa Cruz Biotechnologies, #sc166925, 1:10), MCT4 (Ab Clonal, #A10548, 1:10), superoxide dismutase 2 (Cell Signaling Technologies, #13141, 1:10), and &#x003b1;-Tubulin (Novus Biologicals, #NB100&#x02013;690, 1:50). There were 3 young animals (2 female and 1 male) for each group. The total number of young animals used for this experiment was 6. There were 5 older animals (2 male and 1 female) for each group. The total number of older animals used for this experiment was 6. To determine transduction efficiency, we used HA antibody (#3724, Cell Signaling Technologies, 1:10). Three young animals (2 female and 1 male) per group were used. Three older animals (2 male and 1 female animal) per group were used.</p></sec><sec id="S14"><title>Paraffin Sections and Immunostaining</title><p id="P23">For paraffin sectioning, enucleated eyes were fixed in 4% paraformaldehyde (Thermo Fisher Scientific, #28908) in 1 &#x000d7; PBS at 4&#x000b0;C overnight, followed by dehydration in graded ethanol series (50%, 75%, 95%, 100%). The dehydrated eyes were immersed in paraffin overnight and then embedded. Sections 5-&#x003bc;m thick were cut using a microtome (Leica Biosystems) after 24 hours. The sections were de-paraffinized, rehydrated in ethanol, and used for immunofluorescence staining. Antigen retrieval was performed by boiling the slides in sodium citrate buffer (10mM sodium citrate, pH 6.0) and maintaining at sub-boiling temperature for 10 minutes. The slides were washed in ddH2O for 5 minutes and blocked with 5% donkey serum in 1 &#x000d7; PBST (PBS+0.1% Tween-20) for 30 minutes, then incubated overnight at 4&#x000b0;C with the Anti-GFP antibody (# ab290, Abcam) at 1:50 dilution in the blocking buffer. After 3 washes in 1 &#x000d7; PBST, the slides were incubated for 1 hour at room temperature with secondary antibody. The slides were washed again and mounted with Fluoromount G mounting medium (Thermo Scientific, #00&#x02013;4958-02) and examined by Zeiss LSM 800 confocal microscope (Zeiss). A total of 3 (2 male and 1 female) animals were used.</p></sec><sec id="S15"><title>OCT Measurements</title><p id="P24">Corneal cross-section images were obtained using iVue OCT (Optovue). Corneal thickness measurements were conducted before anterior chamber injections (week 0), 2 weeks after the injection (week 2) and 1 month after the injection (week 4). All measurements were made at the same time of day. At least 3 measurements were made for each eye and averaged. The OCT operator was blinded to the experimental condition. For young animals, 2 male and 1 female <italic toggle="yes">Slc4a11</italic><sup>+/+</sup> and 2 male and 2 female <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals were used for a total number of 7 young animals. For older animals, 2 male and 1 female <italic toggle="yes">Slc4a11</italic><sup>+/+</sup> and 3 male and 3 female <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals were used for a total number of 9 older animals.</p></sec><sec id="S16"><title>Lactate Assay</title><p id="P25">The cornea was dissected, and the epithelium and endothelium were removed. Stroma was placed in preweighed microcentrifuge tubes, crushed in liquid nitrogen, and homogenized in PBS. The sample was centrifuged at 15000g for 15 minutes at 4&#x000b0;C, and the supernatant was removed. Lactate was measured in the supernatant using a lactate assay kit (Biovision #K607) according to the manufacturer&#x02019;s instructions. Two female young animals and 1 male young animal per group, for a total of 6 animals, were used. Three male and 2 female older animals per group, for a total of 10 animals, were used.</p></sec><sec id="S17"><title>MitoSOX Staining</title><p id="P26">Whole corneas were dissected and mounted with the endothelium facing up in small plastic dishes. A volume of 10 &#x003bc;l of 1 mM MitoSOX (#M36008, Thermo Fisher Scientific) was added on the endothelial side and incubated at room temperature for 30 minutes. The corneas were washed 3 times for 5 minutes each with 10 &#x003bc;l of 1 &#x000d7; PBS. After removing all liquid, corneas were positioned in wells of a 96-well plate and fluorescence (excitation: 510 nm, emission: 580 nM) was measured in a microplate reader. Three animals (2 female and 1 male per group) were used for both young and older animals. A total of 12 animals were used in this assay.</p></sec><sec id="S18"><title>Fluorescein Permeability Assay</title><p id="P27">Whole corneas with sclera attached were dissected and placed in small plastic holders with the endothelial side facing upward. Ten microliters of 0.1% sodium fluorescein in bicarbonate-rich Ringer was added on the endothelial side and incubated at room temperature for 15 minutes. The corneas were washed 5 times for 5 minutes each with 10 &#x003bc;l bicarbonate-rich Ringer. After removing all liquid, corneas were positioned in wells of 96-well plate and fluorescence (excitation: 485 nm, emission: 520 nm) was measured in a microplate reader. Three animals (2 male and 1 female per group) were used for both young and older animals. A total of 12 animals were used in this assay.</p></sec><sec id="S19"><title>Intraocular Pressure Measurement</title><p id="P28">By using the Tono-Pen XL (Medtronic), 6 replicate measurements were made in each eye and averaged. Intraocular pressure measurements were made in 3 animals per group (2 male and 1 female) for a total of 6 animals. The Tono-Pen XL operator was blinded to the experimental condition.</p></sec><sec id="S20"><title>Statistical Analysis</title><p id="P29">Error bars represent mean &#x000b1; standard deviation. For 2 groups, statistical significance was calculated using unpaired <italic toggle="yes">t</italic> tests. Analysis of variance with Tukey&#x02019;s multiple comparisons test was used to determine statistical significance if more than 2 groups were analyzed. Statistical analyses were conducted using GraphPad Prism software.</p></sec><sec id="S21"><title>Model Figures</title><p id="P30">The model figures were created with the aid of <ext-link xlink:href="http://BioRender.com" ext-link-type="uri">BioRender.com</ext-link>.</p></sec></sec><sec id="S22"><title>Results</title><sec id="S23"><title>AAV9 Vector Transduces Corneal Endothelium</title><p id="P31">In a glaucoma study, it was determined that intracameral injections of AAV9 serotype can efficiently transduce mouse corneal endothelium.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> Therefore, we decided to test whether anterior chamber injections of AAV9-GFP may be effective in our mouse model.</p><p id="P32">To determine the efficiency of AAV9 serotype transduction into the corneal endothelium, we injected the anterior chamber of 11-week-old <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals with 0.8 &#x003bc;l AAV9-GFP (3.5 &#x000d7; 10<sup>9</sup> Viral Genome). This dose is previously shown to be efficient in transducing the corneal endothelium.<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> In vivo imaging of anesthetized mice revealed strong GFP expression in the central corneal endothelium (<xref rid="F1" ref-type="fig">Fig 1A</xref>). Corneal flat mounts were stained with GFP antibody, and the number of green cells was quantified using Image J analysis. Transduction efficiency was estimated to be 25% &#x000b1; 12% (n = 3, 2 male animals and 1 female animal). Cross-sections of the whole eye revealed strong GFP expression in the endothelial layer of AAV9-GFP injected animals. With GFP antibody staining, we observed nonspecific epithelial staining in both the AAV-GFP injected and the noninjected eyes. Sections with no primary antibody showed no staining (<xref rid="F1" ref-type="fig">Fig 1B</xref>).</p><p id="P33">To rule out any side effects of the viral vector on corneal thickness and intraocular pressure, age-matched <italic toggle="yes">Slc4a11</italic><sup>+/+</sup> and <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals were next injected with AAV9-GFP in 1 eye, while the other eye was not injected. Corneal thickness and intraocular pressure were measured before and 4 weeks after the procedure. No significant changes in corneal thickness were noted in <italic toggle="yes">Slc4a11</italic><sup>+/+</sup> animals between the noninjected and the injected eyes (<xref rid="F1" ref-type="fig">Fig 1C</xref>). In <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> mice, corneal edema was evident in both eyes before the procedure. As expected, both eyes of the KO animals showed increased corneal thickness after 4 weeks (<xref rid="F1" ref-type="fig">Fig 1C</xref>). No significant changes in intraocular pressure were observed in WT and KO animals with AAV9-GFP injections (<xref rid="F1" ref-type="fig">Fig 1D</xref>). Additionally, we conducted slit-lamp microscopy to determine any immune response to the injections. Although slit-lamp imaging may be considered subjective, our observations are consistent with a previous report.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> In addition, we did not observe any significant difference in corneal thickness or evidence of endothelial damage that would be indicative of inflammatory damage between injected and noninjected AAV9-GFP controls.</p></sec><sec id="S24"><title>Reduction in Corneal Edema with AAV9-<italic toggle="yes">HA-Slc4a11</italic></title><p id="P34">The main clinical manifestations of CHED include progressive corneal edema and loss of corneal endothelial cells with age.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> In this set of experiments, we tested whether the reintroduction of the WT allele was sufficient to reverse the disease phenotypes. Adeno-associated virus serotype 9 containing WT allele tagged with HA (AAV9-<italic toggle="yes">HA-Slc4a11</italic>) was injected into the anterior chamber of 1 eye of 5-week-old <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> mice (young animals) or 11-week-old <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> mice (older animals), whereas the other eye was not injected (control eyes). Mice were analyzed at 2 and 4 weeks as illustrated in <xref rid="SD1" ref-type="supplementary-material">Figure S1</xref> (available at <ext-link xlink:href="http://www.ophthalmologyscience.org/" ext-link-type="uri">www.ophthalmologyscience.org</ext-link>).</p><p id="P35"><xref rid="F2" ref-type="fig">Figure 2A</xref> and <xref rid="F2" ref-type="fig">B</xref> show that in the young KO animals, the corneal thickness was not significantly different from the age-matched WT animals at 5 weeks of age (0 day of the injection). A significant increase in corneal thickness was noted in the KO animals&#x02019; noninjected eyes 4 weeks later. However, the AAV9-injected eyes showed less increase in corneal thickness compared with the noninjected eyes. In the older group, increased corneal thickness was evident in the KO animals at week 11 before injection (<xref rid="F2" ref-type="fig">Fig 2C</xref>, <xref rid="F2" ref-type="fig">D</xref>). With AAV9-<italic toggle="yes">HA-Slc4a11</italic> injection, corneal edema did not increase significantly at week 4 compared with week 0 post-injection. However, in the noninjected eye, the cornea continued to thicken with time (<xref rid="F2" ref-type="fig">Fig 2C</xref>, <xref rid="F2" ref-type="fig">D</xref>).</p></sec><sec id="S25"><title><italic toggle="yes">Slc4a11</italic> Transduction</title><p id="P36">Corneal endothelial peelings were isolated 4 weeks after AAV9 injection, and Wes immunoassay was conducted to determine the presence of the HA tag. The molecular weight of Slc4a11 is approximately 100 kDa.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> Expression of HA in this molecular weight range was detected in the AAV-injected eyes (<xref rid="F3" ref-type="fig">Fig 3A</xref>, <xref rid="F3" ref-type="fig">B</xref>), but not in the noninjected WT or KO corneal peelings. Because Slc4a11 antibodies were not used to measure the transduction efficiency, determining whether the protein expression in the injected eyes was comparable to the WT corneal endothelium was not possible.</p></sec><sec id="S26"><title>Decreased Loss of Corneal Endothelial Cell Density</title><p id="P37">To measure corneal endothelial cell density, animals were euthanized at week 4, and the corneal cups were stained with DAPI to visualize nuclei. Image J analysis was conducted to count the number of nuclei in the corneal endothelium using Particle Analysis macro. <xref rid="F4" ref-type="fig">Figure 4A</xref> and <xref rid="F4" ref-type="fig">B</xref> show that endothelial cell density was approximately 12% lower in KO animals at both 9 and 15 weeks of age relative to WT. Both young and older animals injected with AAV9-<italic toggle="yes">HA-Slc4a11</italic> showed less endothelial cell loss with densities slightly, but not significantly, lower than WT.</p><p id="P38">Anterior chamber injections are stressful to the mice, and when both eyes were injected, the animals often died of the stress. Thus, only 1 eye in each mouse belonging to the control and experimental groups were injected. We decided to inject AAV-CAG-Null separately into another group of animals to control for any off-target effects from the virus vector. One eye of 11-week-old <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals was injected, and the other eye was left noninjected. Corneal thickness (<xref rid="SD1" ref-type="supplementary-material">Fig S2A</xref>, <xref rid="SD1" ref-type="supplementary-material">B</xref>) and corneal endothelial densities (<xref rid="SD1" ref-type="supplementary-material">Fig S2C</xref>, <xref rid="SD1" ref-type="supplementary-material">D</xref>) were comparable between the virus-injected and noninjected eyes.</p></sec><sec id="S27"><title>Reduction in Stromal Lactate Levels and Increase in Lactate Transporter Expression with AAV9-<italic toggle="yes">HA-Slc4a11</italic></title><p id="P39">In <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals, reduction in corneal endothelial pump function leads to corneal edema.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> Depressed pump function results from reduced lactate efflux from the cornea leading to the accumulation of lactate in the stroma,<sup><xref rid="R21" ref-type="bibr">21</xref></sup> which progresses with age in the <italic toggle="yes">Slc4a11</italic> KO.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> Lactate transporters, MCT1, 2, and 4, are active in the corneal endothelium,<sup><xref rid="R21" ref-type="bibr">21</xref>&#x02013;<xref rid="R23" ref-type="bibr">23</xref></sup> and their functions are crucial in the maintenance of corneal deturgescence<sup><xref rid="R1" ref-type="bibr">1</xref></sup> (<xref rid="F5" ref-type="fig">Fig 5A</xref>). <xref rid="F5" ref-type="fig">Figure 5B</xref> shows that concomitant with corneal thickness changes, AAV9-<italic toggle="yes">HA-Slc4a11</italic> injection caused a 30% reduction in corneal [lactate] in young animals. In the older animals, which started with higher [lactate], a small but statistically insignificant decrease in [lactate] was observed. As the [lactate] reduced with AAV9-<italic toggle="yes">HA-Slc4a11</italic> injection, we next determined whether lactate transporters&#x02019; protein expression was affected with the introduction of <italic toggle="yes">Slc4a11</italic>. In the young animals, slight upregulation of MCT1 and 2 protein levels was observed (<xref rid="F5" ref-type="fig">Fig 5C</xref>, <xref rid="F5" ref-type="fig">D</xref>); however, MCT4 expression increased significantly with AAV9-<italic toggle="yes">HA-Slc4a11</italic> injection (<xref rid="F5" ref-type="fig">Fig 5C</xref>, <xref rid="F5" ref-type="fig">D</xref>). In the older animals, lactate transporter expressions were elevated with the introduction of the AAV, but these levels were not significantly improved from those observed in noninjected eyes (<xref rid="F5" ref-type="fig">Fig 5C</xref>, <xref rid="F5" ref-type="fig">E</xref>).</p></sec><sec id="S28"><title>AAV9-<italic toggle="yes">HA-Slc4a11</italic> Injection Improves Endothelial Morphology and Barrier</title><p id="P40">Cell membrane integrity is essential for the normal functioning of the endothelial pump. The shape and organization of corneal endothelial cells are aberrant in CHED.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> A recent study from our laboratory has revealed abnormal cytoskeletal structure of the corneal endothelium with the loss of <italic toggle="yes">Slc4a11</italic>.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> To assess the cytoskeleton, corneal flat mounts were stained with phalloidin to visualize the F-actin network. With AAV9-<italic toggle="yes">HA-Slc4a11</italic>, the phalloidin staining pattern appeared more organized in both young and older animals when compared with noninjected controls (red ellipses in <xref rid="F6" ref-type="fig">Fig 6A</xref>). Moreover, the phalloidin fluorescence intensities of the AAV injected eyes were comparable to that of WT in the young animals (<xref rid="F6" ref-type="fig">Fig 6B</xref>).</p><p id="P41">Endothelial cells express the tight junction protein ZO-1.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> The expression pattern of ZO-1 is incomplete, which accounts for a weak endothelial barrier that allows the passage of nutrients and other molecules into the stroma.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Increased cell size is observed in <italic toggle="yes">Slc4a11</italic> KO corneal endothelium.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup> To assess cell size, corneal cups were stained with ZO-1. In the young noninjected eyes, the endothelial cells appeared larger when compared with WT cells. In the older animals, cell area was significantly altered between WT and KO animals. The AAV9-<italic toggle="yes">HA-Slc4a11</italic> injections improved the cell area in <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> young and older animals (<xref rid="F6" ref-type="fig">Fig 6C</xref>, <xref rid="F6" ref-type="fig">D</xref>).</p><p id="P42">Paracellular permeability of endothelial cells was measured using fluorescein penetration of the endothelium. <xref rid="F7" ref-type="fig">Figure 7A</xref> shows that KO endothelium has significantly higher fluorescein penetration consistent with a dysfunctional barrier function. With AAV9-<italic toggle="yes">HA-Slc4a11</italic> injection, fluorescein permeability of the endothelium was significantly reduced in young animals. Small but significant improvement was also observed between noninjected and AAV9-<italic toggle="yes">HA-Slc4a11</italic> injected eyes of older animals.</p></sec><sec id="S29"><title>Oxidative Stress</title><p id="P43">Loss of <italic toggle="yes">Slc4a11</italic> is associated with mitochondrial oxidative stress.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> To determine whether AAV9-<italic toggle="yes">HA-Slc4a11</italic> injection reduces reactive oxygen species (ROS) levels, we stained the corneal cups with mitochondria superoxide marker, MitoSOX. Quantification of fluorescence intensity revealed significant reduction in ROS levels in young animals and a small but not statistically significant decrease in the older animals injected with AAV9-<italic toggle="yes">HA-Slc4a11</italic> (<xref rid="F7" ref-type="fig">Fig 7B</xref>). Superoxide dismutase 2 is a mitochondria-specific ROS quencher known to function in the corneal endothelium.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> Significant reduction of superoxide dismutase 2 levels was observed in both young and older <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals. With AAV9-<italic toggle="yes">HA-Slc4a11</italic>, a significant increase in the levels of this protein was observed in young but not older animals (<xref rid="F7" ref-type="fig">Fig 7C</xref>, <xref rid="F7" ref-type="fig">D</xref>).</p></sec></sec><sec id="S30"><title>Discussion</title><p id="P44">We show the successful reversal of the disease phenotype in a CHED mouse model using AAV9-<italic toggle="yes">HA-Slc4a11</italic>. There are precedents for the rescue of disease states in the eye by direct transfection of WT genes into dysfunctional tissue.<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup> Improvements in intraocular pressure and aqueous humor outflow were previously demonstrated by AAV-mediated transduction of Matrix-Metallo-Proteinase 3 into the corneal endothelium of glaucomatous mice.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> Recently, it was shown that AAV-mediated knockdown of mutant collagen 8a2 can improve the disease associated phenotype in a mouse model for early-onset Fuchs&#x02019; endothelial corneal dystrophy.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> In the current study, we have shown that replacement of the WT gene into <italic toggle="yes">Slc4a11</italic><sup><italic toggle="yes">&#x02212;</italic>/&#x02212;</sup> corneal endothelium can improve the disease phenotype related to CHED in a KO mouse model.</p><p id="P45">In CHED, structural changes in the cornea and edema progress with age.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> Therefore, we hypothesized that age might affect the efficacy with which the disease phenotypes can be reversed by gene therapy. We conducted viral injections in CHED mice of 2 different age groups: young mice (5 weeks old) in which the corneal edema and endothelial cell loss are mild and older mice (11 weeks old) in which these changes are more apparent. Both female and male mice were used for all our experiments, and the gender of the animal had no effect on the measurements. Studies from our laboratory have shown that lactate efflux from the stroma is compromised in endothelial dystrophies leading to increased [lactate] in the cornea.<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> With AAV9-<italic toggle="yes">HA-Slc4a11</italic> injection, concomitant with reduced edema, we observed a significant reduction of [lactate] in the young KO animal eyes compared with noninjected KO eyes. In the older animals, consistent with minimal improvement in corneal thickness, there was a small but not significant reduction in [lactate]. Supporting these observations, the expression of the major lactate transporters in the corneal endothelium increased with AAV9-<italic toggle="yes">HA-Slc4a11</italic> in young animals but less in older animals.</p><p id="P46">Endothelial pump function relies on both lactate transport and an intact osmotic barrier.<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> Changes in cell shape in <italic toggle="yes">Slc4a11</italic> KO corneal endothelium have been reported.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> In <italic toggle="yes">Slc4a11</italic> KO corneal endothelial cells, aberrations in actin cytoskeleton assembly, tight junction organization, cell shape changes, and increased paracellular permeability were observed.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> In young animals, AAV9-<italic toggle="yes">HA-Slc4a11</italic> introduction restored all of these changes to the levels comparable to those observed in WT animals. However, older animals showed little improvement in these parameters.</p><p id="P47">Our data show that AAV9-<italic toggle="yes">HA-Slc4a11</italic> introduction into the anterior chamber can reverse the major disease phenotype associated with CHED. It is a viable option that can bypass invasive treatments such as corneal transplantation. Furthermore, we show that AAV9 transduction into the corneal endothelium does not affect intraocular pressure or cause inflammation, indicating a safe treatment alternative. Finally, we provide evidence that the gene therapy avenue is most effective during the initial stages of the disease and has limited potential once the structural integrity of the corneal endothelial layer or stroma is significantly affected.</p><p id="P48">Oxidative stress is likely the cause of the altered gene expression and paracellular permeability because quenching ROS can reduce corneal edema.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup> Consistent with this notion, we found that reintroduction of <italic toggle="yes">Slc4a11</italic> reduces mitochondrial superoxide levels within the endothelium. This suggests that ROS quenching can temporarily preserve cell function until gene replacement is achieved. Mutations in <italic toggle="yes">Slc4a11</italic> are the most common cause of CHED.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> Congenital hereditary endothelial dystrophy is common among people in India, Saudi Arabia, and Iran. Several studies have shown that approximately 100% of the CHED patients had mutations in <italic toggle="yes">Slc4a11</italic>.<sup><xref rid="R31" ref-type="bibr">31</xref>&#x02013;<xref rid="R33" ref-type="bibr">33</xref></sup> There are several <italic toggle="yes">Slc4a11</italic> mutations associated with CHED.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R34" ref-type="bibr">34</xref></sup> The approach in human patients could be via a CRISPR repair of the mutation or overexpression of WT <italic toggle="yes">Slc4a11</italic> as done here. The latter approach may be limited by dominant negative associations.<sup><xref rid="R35" ref-type="bibr">35</xref></sup> In any approach, therapy must start at the earliest stage possible before cell loss and structural changes become irreversible. One of the limitations of our study is the low transduction efficiency of the corneal endothelium with the AAV9 serotype. Future studies may use different AAV serotypes to improve this, which may lead to the improvement of disease-associated symptoms in older animals. As done previously,<sup><xref rid="R19" ref-type="bibr">19</xref></sup> we conducted slit-lamp imaging to determine any signs of inflammation. Future studies may consider immunostaining for macrophages in corneal sections to rule out any inflammation from AAV injections.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data"><label>1</label><media xlink:href="NIHMS1829272-supplement-1.pdf" id="d64e937" position="anchor"/></supplementary-material></sec></body><back><ack id="S31"><title>Acknowledgments</title><p id="P49">The authors thank Dr. Shimin Li for support and expert advice and Dr. Catherine Cheng for the use of Protein Simple Wes system and Zeiss LSM 800 confocal microscope.</p><sec id="S32"><title>Financial Support:</title><p id="P50">R01EY031321 (J.A.B.) and R01EY008834 (J.A.B.), National Institutes of Health/National Center for Advancing Translational Sciences CTSI TL1 TR002531 and UL1 TR002529 (2018&#x02013;2020) (R.S.), and Knights Templar Eye Foundation career starter grant (2019&#x02013;2021) (R.S.). The funding organizations had no role in the design or conduct of this research.</p></sec></ack><fn-group><fn id="FN2"><p id="P51">Disclosure(s):</p><p id="P52">All authors have completed and submitted the ICMJE disclosures form.</p><p id="P53">The author(s) have no proprietary or commercial interest in any materials discussed in this article.</p></fn><fn id="FN3"><p id="P54">HUMAN SUBJECTS: Human subjects were not included in this study. All animal experiments were conducted in accordance with institutional guidelines and the current regulations of the National Institutes of Health, the United States Department of Health and Human Services, the United States Department of Agriculture, and the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. All research adhered to the tenets of the Declaration of Helsinki. Individual patient-level consent was not required.</p></fn></fn-group><glossary><title>Abbreviations and Acronyms:</title><def-list><def-item><term>AAV</term><def><p id="P55">adeno-associated virus</p></def></def-item><def-item><term>AAV9</term><def><p id="P56">adeno-associated virus serotype 9</p></def></def-item><def-item><term>CAG</term><def><p id="P57">chicken &#x003b2;-actin</p></def></def-item><def-item><term>CHED</term><def><p id="P58">congenital hereditary endothelial dystrophy</p></def></def-item><def-item><term>GFP</term><def><p id="P59">green fluorescent protein</p></def></def-item><def-item><term>HA</term><def><p id="P60">hemagglutinin</p></def></def-item><def-item><term>KO<italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup></term><def><p id="P61">knockout</p></def></def-item><def-item><term>MCT</term><def><p id="P62">monocarboxylate transporter</p></def></def-item><def-item><term>PBS</term><def><p id="P63">phosphate-buffered saline</p></def></def-item><def-item><term>WT<italic toggle="yes">Slc4a11</italic><sup>+/+</sup></term><def><p id="P64">wild-type</p></def></def-item><def-item><term>ZO-1</term><def><p id="P65">zonula occludens 1</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Bonanno</surname><given-names>JA</given-names></name>. <article-title>Molecular mechanisms underlying the corneal endothelial pump</article-title>. <source>Exp Eye Res</source>. <year>2012</year>;<volume>95</volume>:<fpage>2</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">21693119</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Bourne</surname><given-names>WM</given-names></name>. <article-title>Biology of the corneal endothelium in health and disease</article-title>. <source>Eye</source>. <year>2003</year>;<volume>17</volume>:<fpage>912</fpage>&#x02013;<lpage>918</lpage>.<pub-id pub-id-type="pmid">14631396</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Vanathi</surname><given-names>M</given-names></name>, <name><surname>Panda</surname><given-names>A</given-names></name>, <name><surname>Vengayil</surname><given-names>S</given-names></name>, <etal/>
<article-title>Pediatric keratoplasty</article-title>. <source>Surv Ophthalmol</source>. <year>2009</year>;<volume>54</volume>:<fpage>245</fpage>&#x02013;<lpage>271</lpage>.<pub-id pub-id-type="pmid">19298903</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Vithana</surname><given-names>EN</given-names></name>, <name><surname>Morgan</surname><given-names>P</given-names></name>, <name><surname>Sundaresan</surname><given-names>P</given-names></name>, <etal/>
<article-title>Mutations in sodium-borate cotransporter SLC4A11 cause recessive congenital hereditary endothelial dystrophy (CHED2)</article-title>. <source>Nat Genet</source>. <year>2006</year>;<volume>38</volume>:<fpage>755</fpage>&#x02013;<lpage>757</lpage>.<pub-id pub-id-type="pmid">16767101</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Han</surname><given-names>SB</given-names></name>, <name><surname>Ang</surname><given-names>H-P</given-names></name>, <name><surname>Poh</surname><given-names>R</given-names></name>, <etal/>
<article-title>Mice with a targeted disruption of Slc4a11 model the progressive corneal changes of congenital hereditary endothelial dystrophy</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2013</year>;<volume>54</volume>:<fpage>6179</fpage>&#x02013;<lpage>6189</lpage>.<pub-id pub-id-type="pmid">23942972</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Ogando</surname><given-names>DG</given-names></name>, <name><surname>Choi</surname><given-names>M</given-names></name>, <name><surname>Shyam</surname><given-names>R</given-names></name>, <etal/>
<article-title>Ammonia sensitive SLC4A11 mitochondrial uncoupling reduces glutamine induced oxidative stress</article-title>. <source>Redox Biol</source>. <year>2019</year>;<volume>26</volume>:<fpage>101260</fpage>.<pub-id pub-id-type="pmid">31254733</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Guha</surname><given-names>S</given-names></name>, <name><surname>Chaurasia</surname><given-names>S</given-names></name>, <name><surname>Ramachandran</surname><given-names>C</given-names></name>, <name><surname>Roy</surname><given-names>S</given-names></name>. <article-title>SLC4A11 depletion impairs NRF2 mediated antioxidant signaling and increases reactive oxygen species in human corneal endothelial cells during oxidative stress</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>:<fpage>4074</fpage>.<pub-id pub-id-type="pmid">28642546</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Aldave</surname><given-names>AJ</given-names></name>, <name><surname>Han</surname><given-names>J</given-names></name>, <name><surname>Frausto</surname><given-names>RF</given-names></name>. <article-title>Genetics of the corneal endothelial dystrophies: an evidence-based review</article-title>. <source>Clin Genet</source>. <year>2013</year>;<volume>84</volume>:<fpage>109</fpage>&#x02013;<lpage>119</lpage>.<pub-id pub-id-type="pmid">23662738</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Ogando</surname><given-names>DG</given-names></name>, <name><surname>Shyam</surname><given-names>R</given-names></name>, <name><surname>Kim</surname><given-names>ET</given-names></name>, <etal/>
<article-title>Inducible Slc4a11 knockout triggers corneal edema through perturbation of corneal endothelial pump</article-title>. <source>Investig Opthalmology Vis Sci</source>. <year>2021</year>;<volume>62</volume>:<fpage>28</fpage>.</mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>S</given-names></name>, <name><surname>Shyam</surname><given-names>R</given-names></name>, <name><surname>Ogando</surname><given-names>DG</given-names></name>, <name><surname>Bonanno</surname><given-names>JA</given-names></name>. <article-title>Bicarbonate activates glycolysis and lactate production in corneal endothelial cells by increased pHi</article-title>. <source>Exp Eye Res</source>. <year>2020</year>;<volume>199</volume>:<fpage>108193</fpage>.<pub-id pub-id-type="pmid">32818510</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Busin</surname><given-names>M</given-names></name>
<article-title>Descemet-stripping automated endothelial keratoplasty for congenital hereditary endothelial dystrophy</article-title>. <source>Arch Ophthalmol</source>. <year>2011</year>;<volume>129</volume>:<fpage>1140</fpage>.<pub-id pub-id-type="pmid">21555597</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Tan</surname><given-names>DT</given-names></name>, <name><surname>Dart</surname><given-names>JK</given-names></name>, <name><surname>Holland</surname><given-names>EJ</given-names></name>, <name><surname>Kinoshita</surname><given-names>S</given-names></name>. <article-title>Corneal transplantation</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>379</volume>:<fpage>1749</fpage>&#x02013;<lpage>1761</lpage>.<pub-id pub-id-type="pmid">22559901</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="book"><name><surname>de By</surname><given-names>TMMH</given-names></name>. <part-title>Shortage in the face of plenty: Improving the allocation of corneas for transplantation</part-title>. In: <source>Adequate HLA Matching in Keratoplasty</source>. <publisher-loc>Basel</publisher-loc>: <publisher-name>Karger</publisher-name>; <year>2002</year>:<fpage>56</fpage>&#x02013;<lpage>61</lpage>. <comment><ext-link xlink:href="https://www.karger.com/Article/Abstract/67656" ext-link-type="uri">https://www.karger.com/Article/Abstract/67656</ext-link></comment>.</mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Fuest</surname><given-names>M</given-names></name>, <name><surname>Yam</surname><given-names>GH-F</given-names></name>, <name><surname>Mehta</surname><given-names>JS</given-names></name>, <name><surname>Duarte Campos</surname><given-names>DF</given-names></name>. <article-title>Prospects and challenges of translational corneal bioprinting</article-title>. <source>Bioengineering</source>. <year>2020</year>;<volume>7</volume>:<fpage>71</fpage>.</mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Borr&#x000e1;s</surname><given-names>T</given-names></name>, <name><surname>Xue</surname><given-names>W</given-names></name>, <name><surname>Choi</surname><given-names>VW</given-names></name>, <etal/>
<article-title>Mechanisms of AAV transduction in glaucoma-associated human trabecular meshwork cells</article-title>. <source>J Gene Med</source>. <year>2006</year>;<volume>8</volume>:<fpage>589</fpage>&#x02013;<lpage>602</lpage>.<pub-id pub-id-type="pmid">16506246</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Barker</surname><given-names>SE</given-names></name>, <name><surname>Broderick</surname><given-names>CA</given-names></name>, <name><surname>Robbie</surname><given-names>SJ</given-names></name>, <etal/>
<article-title>Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice</article-title>. <source>J Gene Med</source>. <year>2009</year>;<volume>11</volume>:<fpage>486</fpage>&#x02013;<lpage>497</lpage>.<pub-id pub-id-type="pmid">19340848</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Uehara</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Pereira</surname><given-names>F</given-names></name>, <etal/>
<article-title>Start codon disruption with CRISPR/Cas9 prevents murine Fuchs&#x02019; endothelial corneal dystrophy</article-title>. <source>Elife</source>. <year>2021</year>;<volume>10</volume>.</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Bastola</surname><given-names>P</given-names></name>, <name><surname>Song</surname><given-names>L</given-names></name>, <name><surname>Gilger</surname><given-names>BC</given-names></name>, <name><surname>Hirsch</surname><given-names>ML</given-names></name>. <article-title>Adeno-associated virus mediated gene therapy for corneal diseases</article-title>. <source>Pharmaceutics</source>. <year>2020</year>;<volume>12</volume>:<fpage>767</fpage>.</mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>O&#x02019;Callaghan</surname><given-names>J</given-names></name>, <name><surname>Crosbie</surname><given-names>DE</given-names></name>, <name><surname>Cassidy</surname><given-names>PS</given-names></name>, <etal/>
<article-title>Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma</article-title>. <source>Hum Mol Genet</source>. <year>2017</year>;<volume>26</volume>: <fpage>1230</fpage>&#x02013;<lpage>1246</lpage>.<pub-id pub-id-type="pmid">28158775</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>S</given-names></name>, <name><surname>Kim</surname><given-names>E</given-names></name>, <name><surname>Ogando</surname><given-names>DG</given-names></name>, <name><surname>Bonanno</surname><given-names>JA</given-names></name>. <article-title>Corneal endothelial pump coupling to lactic acid efflux in the rabbit and mouse</article-title>. <source>Invest Opthalmology Vis Sci</source>. <year>2020</year>;<volume>61</volume>:<fpage>7</fpage>.</mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>S</given-names></name>, <name><surname>Kim</surname><given-names>E</given-names></name>, <name><surname>Bonanno</surname><given-names>JA</given-names></name>. <article-title>Fluid transport by the cornea endothelium is dependent on buffering lactic acid efflux</article-title>. <source>Am J Physiol Physiol</source>. <year>2016</year>;<volume>311</volume>:<fpage>C116</fpage>&#x02013;<lpage>C126</lpage>.</mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>S</given-names></name>, <name><surname>Nguyen</surname><given-names>TT</given-names></name>, <name><surname>Bonanno</surname><given-names>JA</given-names></name>. <article-title>CD147 required for corneal endothelial lactate transport</article-title>. <source>Investig Ophthalmol Vis Sci</source>. <year>2014</year>;<volume>55</volume>:<fpage>4673</fpage>&#x02013;<lpage>4681</lpage>.<pub-id pub-id-type="pmid">24970254</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Nguyen</surname><given-names>TT</given-names></name>, <name><surname>Bonanno</surname><given-names>JA</given-names></name>. <article-title>Lactate-H + transport is a significant component of the in vivo corneal endothelial pump</article-title>. <source>Invest Opthalmology Vis Sci</source>. <year>2012</year>;<volume>53</volume>:<fpage>2020</fpage>.</mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Feizi</surname><given-names>S</given-names></name>
<article-title>Corneal endothelial cell dysfunction: etiologies and management</article-title>. <source>Ther Adv Ophthalmol</source>. <year>2018</year>;<volume>10</volume>, <fpage>251584141881580</fpage>.</mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name><surname>Schmedt</surname><given-names>T</given-names></name>, <name><surname>Silva</surname><given-names>MM</given-names></name>, <name><surname>Ziaei</surname><given-names>A</given-names></name>, <etal/>
<article-title>Molecular bases of corneal endothelial dystrophies</article-title>. <source>Am J Pathol</source>. <year>2010</year>;<volume>95</volume>:<fpage>24</fpage>&#x02013;<lpage>34</lpage>.</mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>C</given-names></name>, <name><surname>Ogando</surname><given-names>D</given-names></name>, <name><surname>Bonanno</surname><given-names>JA</given-names></name>. <article-title>SOD2 contributes to antioxidative capacity in rabbit corneal endothelial cells</article-title>. <source>Mol Vis</source>. <year>2011</year>;<volume>17</volume>:<fpage>2473</fpage>&#x02013;<lpage>2481</lpage>.<pub-id pub-id-type="pmid">21976958</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name><surname>Pierce</surname><given-names>EA</given-names></name>, <name><surname>Bennett</surname><given-names>J</given-names></name>. <article-title>The status of RPE65 gene therapy trials: safety and efficacy</article-title>. <source>Cold Spring Harb Perspect Med</source>. <year>2015</year>;<volume>5</volume>: <fpage>a017285</fpage>.<pub-id pub-id-type="pmid">25635059</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Petit</surname><given-names>L</given-names></name>, <name><surname>Khanna</surname><given-names>H</given-names></name>, <name><surname>Punzo</surname><given-names>C</given-names></name>. <article-title>Advances in gene therapy for diseases of the eye</article-title>. <source>Hum Gene Ther</source>. <year>2016</year>;<volume>27</volume>:<fpage>563</fpage>&#x02013;<lpage>579</lpage>.<pub-id pub-id-type="pmid">27178388</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Shyam</surname><given-names>R</given-names></name>, <name><surname>Ogando</surname><given-names>DG</given-names></name>, <name><surname>Choi</surname><given-names>M</given-names></name>, <etal/>
<article-title>Mitochondrial ROS induced lysosomal dysfunction and autophagy impairment in an animal model of congenital hereditary endothelial dystrophy</article-title>. <source>Investig Opthalmology Vis Sci</source>. <year>2021</year>;<volume>62</volume>:<fpage>15</fpage>.</mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Patel</surname><given-names>SP</given-names></name>, <name><surname>Parker</surname><given-names>MD</given-names></name>. <article-title>SLC4A11 and the pathophysiology of congenital hereditary endothelial dystrophy</article-title>. <source>Biomed Res Int</source>. <year>2015</year>;<volume>2015</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name><surname>Aldahmesh</surname><given-names>MA</given-names></name>, <name><surname>Khan</surname><given-names>AO</given-names></name>, <name><surname>Meyer</surname><given-names>BF</given-names></name>, <name><surname>Alkuraya</surname><given-names>FS</given-names></name>. <article-title>Mutational spectrum of SLC4A11 in autosomal recessive CHED in Saudi Arabia</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2009</year>;<volume>50</volume>: <fpage>4142</fpage>&#x02013;<lpage>4145</lpage>.<pub-id pub-id-type="pmid">19369245</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name><surname>Moazzeni</surname><given-names>H</given-names></name>, <name><surname>Javadi</surname><given-names>MA</given-names></name>, <name><surname>Asgari</surname><given-names>D</given-names></name>, <etal/>
<article-title>Observation of nine previously reported and 10 non-reported <italic toggle="yes">SLC4A11</italic> mutations among 20 Iranian CHED probands and identification of an <italic toggle="yes">MPDZ</italic> mutation as possible cause of CHED and FECD in one family</article-title>. <source>Br J Ophthalmol</source>. <year>2020</year>;<volume>104</volume>: <fpage>1621</fpage>&#x02013;<lpage>1628</lpage>.<pub-id pub-id-type="pmid">31420327</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><name><surname>Hemadevi</surname><given-names>B</given-names></name>
<article-title>Identification of mutations in the SLC4A11 gene in patients with recessive congenital hereditary endothelial dystrophy</article-title>. <source>Arch Ophthalmol</source>. <year>2008</year>;<volume>126</volume>:<fpage>700</fpage>.<pub-id pub-id-type="pmid">18474783</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name><surname>Kao</surname><given-names>L</given-names></name>, <name><surname>Azimov</surname><given-names>R</given-names></name>, <name><surname>Shao</surname><given-names>XM</given-names></name>, <etal/>
<article-title>Multifunctional ion transport properties of human SLC4A11: comparison of the SLC4A11-B and SLC4A11-C variants</article-title>. <source>Am J Physiol Cell Physiol</source>. <year>2016</year>;<volume>311</volume>:<fpage>C820</fpage>&#x02013;<lpage>C830</lpage>.<pub-id pub-id-type="pmid">27581649</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name><surname>Malhotra</surname><given-names>D</given-names></name>, <name><surname>Loganathan</surname><given-names>SK</given-names></name>, <name><surname>Chiu</surname><given-names>AM</given-names></name>, <etal/>
<article-title>Human corneal expression of SLC4A11, a gene mutated in endothelial corneal dystrophies</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>:<fpage>9681</fpage>.<pub-id pub-id-type="pmid">31273259</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Figure 1.</label><caption><p id="P66">Adeno-associated virus serotype 9 green fluorescent protein (AAV9-GFP) is transduced into the corneal endothelium. <bold>A,</bold> Fluorescence microscopy of mouse eye 2 weeks after AAV9-GFP injection. Note endothelial fluorescence over a uniform background of lens fluorescence. Scale bar &#x02013;500 &#x003bc;m (left and right images) and 200 &#x003bc;m (middle image). Flat mount of the cornea after GFP antibody staining in green and DAPI in Blue. Scale bar &#x02212;20 &#x003bc;m. <bold>B,</bold> Cross-section of AAV9-GFP injected and noninjected eyes stained with GFP antibody. No primary antibody sections were only treated with secondary antibody. Scale bar &#x02212; 20 &#x003bc;m. <bold>C,</bold> Corneal thickness measurements of <italic toggle="yes">Slc4a11</italic><sup>+/+</sup> and <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals before and 4 weeks after AAV9-GFP injections. Noninjected eyes of the same animals were used as control. <bold>D,</bold> Intraocular pressure measurements of <italic toggle="yes">Slc4a11</italic><sup>+/+</sup> and <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals before and 4 weeks after AAV9-GFP injections. Noninjected eyes of the same animals were used as control: n = 3 (2 male and 1 female) per group for a total of 6 animals. ns = not significant, <italic toggle="yes">P</italic> &#x02265; 0.1 (1-way analysis of variance [ANOVA] with Tukey&#x02019;s multiple comparisons test).</p></caption><graphic xlink:href="nihms-1829272-f0001" position="float"/></fig><fig position="float" id="F2"><label>Figure 2.</label><caption><p id="P67">Corneal edema is reduced with AAV9-<italic toggle="yes">HA-Slc4a11</italic>. <bold>A,</bold> Representative OCT images of <italic toggle="yes">Slc4a11</italic><sup>+/+</sup>, noninjected <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup>, and AAV9-<italic toggle="yes">HA-Slc4a11</italic> injected <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> eyes from young animals. <bold>B,</bold> Quantification of data from <bold>A</bold> (n = 4, 2 male and 2 female Slc4a11<sup>+/+</sup>, 2 male and 2 female <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals were used). <bold>C,</bold> Representative OCT images of <italic toggle="yes">Slc4a11</italic><sup>+/+</sup>, noninjected <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup>, and AAV9-<italic toggle="yes">HA-Slc4a11</italic> injected <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> eyes from older animals (n = 3&#x02013;6, 2 male and 1 female Slc4a11<sup>+/+</sup>, 3 male and 3 female <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals were used). <bold>D,</bold> Quantification of data from C. Mean &#x000b1; standard deviation (SD). ns = not significant, <italic toggle="yes">P</italic> &#x02265; 0.1 (1-way ANOVA with Tukey&#x02019;s multiple comparisons test). AAV9-HA = adeno-associated virus serotype 9 hemagglutinin; OD = right eye; OS = left eye.</p></caption><graphic xlink:href="nihms-1829272-f0002" position="float"/></fig><fig position="float" id="F3"><label>Figure 3.</label><caption><p id="P68">Transduction of AAV9-<italic toggle="yes">HA-Slc4a11</italic> into the corneal endothelium of <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> (knockout [KO]) animals. <bold>A,</bold> Representative Wes immunoassay of corneal endothelial peelings, from <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> young or older animals, KO(Y) and KO(O), respectively, 4 weeks after AAV9-<italic toggle="yes">HA-Slc4a11</italic> injections, using HA antibody. Age-matched noninjected <italic toggle="yes">Slc4a11</italic><sup>+/+</sup> (wild-type [WT]) or <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> (KO) corneal endothelia were used as negative controls, &#x00251;-tubulin was used as loading control. n = 3, 1 male and 2 female (young animals) and 2 male and 1 female (older animals). <bold>B,</bold> Quantification of data from <bold>A</bold>. Mean &#x000b1; SD. ns = not significant, <italic toggle="yes">P</italic> &#x02265; 0.1 (1-way ANOVA with Tukey&#x02019;s multiple comparisons test). AAV9-HA = adeno-associated virus serotype 9 hemagglutinin.</p></caption><graphic xlink:href="nihms-1829272-f0003" position="float"/></fig><fig position="float" id="F4"><label>Figure 4.</label><caption><p id="P69">Decreased corneal endothelial cell loss with AAV9-<italic toggle="yes">HA-Slc4a11</italic>. <bold>A,</bold> Corneal endothelial cell density of young and older <italic toggle="yes">Slc4a11</italic><sup>+/+</sup>, noninjected <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup>, and AAV9-<italic toggle="yes">HA-Slc4a11</italic> injected <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals visualized with DAPI staining of corneal flat mounts. Scale bar &#x02212; 10 &#x003bc;m. <bold>B,</bold> Quantification of cell density from <bold>A.</bold> Three animals (2 female and 1 male) were used for each group. Seven images were obtained from each group to quantify the average cell density. Mean &#x000b1; SD. *ns = not significant, <italic toggle="yes">P</italic> &#x02265; 0.1 (1-way ANOVA with Tukey&#x02019;s multiple comparisons test). AAV9-HA = adeno-associated virus serotype 9 hemagglutinin.</p></caption><graphic xlink:href="nihms-1829272-f0004" position="float"/></fig><fig position="float" id="F5"><label>Figure 5.</label><caption><p id="P70">Lactate levels are reduced and lactate transporter expressions are increased with AAV9-<italic toggle="yes">HA-Slc4a11</italic> in young animals. <bold>A,</bold> Schematic of the corneal layers and a diagram of lactate movement from the cornea into the anterior chamber with the aid of lactate transporters, monocarboxylate transporter (MCT)1, 2, and 4.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup>
<bold>B,</bold> Quantification of lactate levels in <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals. n = 3 (young animals, 2 female and 1 male for each group), n = 5 (older animals, 3 male and 2 female for each group). Mean &#x000b1; SD. ns = not significant, <italic toggle="yes">P</italic> &#x02265; 0.1 (1-way ANOVA with Tukey&#x02019;s multiple comparisons test). (C) Representative Wes immunoassay of young and older animals for lactate transporters MCT1, MCT2, MCT4, and loading control <bold>&#x00251;</bold>-tubulin. <bold>D,</bold> Quantification of Wes immunoassay results from young animals. n = 3, 1 male and 2 females per group. ns = not significant, <italic toggle="yes">P</italic> &#x02265; 0.1 (1-way ANOVA with Tukey&#x02019;s multiple comparisons test). <bold>E</bold>, Quantification of Wes immunoassay results from older animals. n = 3, 2 males and 1 female per group. ns = not significant, <italic toggle="yes">P</italic> = 0.05. For MCT1, the band closest to 66 KDa was used for quantification. Lower molecular weight band was used for MCT4 quantification. AAV9-HA = adeno-associated virus serotype 9 hemagglutinin; MCT = monocarboxylate transporter.</p></caption><graphic xlink:href="nihms-1829272-f0005" position="float"/></fig><fig position="float" id="F6"><label>Figure 6.</label><caption><p id="P71">Cytoskeletal structure and tight junction architecture are improved with AAV9-<italic toggle="yes">HA-Slc4a11.</italic>
<bold>A,</bold> Phalloidin staining of corneal endothelia to visualize F-actin cytoskeleton network in <italic toggle="yes">Slc4a11</italic><sup>+/+</sup>, noninjected <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> and AAV9-<italic toggle="yes">HA-Slc4a11</italic> injected <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup>animals. <bold>B,</bold> Quantification of fluorescence intensity of phalloidin staining. <bold>C,</bold> ZO-1 staining of the corneal endothelia to visualize tight junction structure in <italic toggle="yes">Slc4a11</italic><sup>+/+</sup>, noninjected <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> and AAV9-<italic toggle="yes">HA-Slc4a11</italic> injected <italic toggle="yes">Slc4a11</italic><sup>&#x02212;/&#x02212;</sup> animals. <bold>D,</bold> Quantification of cell area. <bold>B</bold> and <bold>D,</bold> Three animals (2 females and 1 male) were used for each group. Seven images were obtained from each group to quantify the average cell density. Mean &#x000b1; SD. *<italic toggle="yes">P</italic> &#x0003c; 0.05, **<italic toggle="yes">P</italic> &#x0003c; 0.01, ***<italic toggle="yes">P</italic> &#x0003c; 0.001, ****<italic toggle="yes">P</italic> &#x0003c; 0.0001. ns = not significant (1-way ANOVA with Tukey&#x02019;s multiple comparisons test). AAV9-HA = adeno-associated virus serotype 9 hemagglutinin.</p></caption><graphic xlink:href="nihms-1829272-f0006" position="float"/></fig><fig position="float" id="F7"><label>Figure 7.</label><caption><p id="P72">Reduction in paracellular permeability and mitochondrial ROS with AAV9-<italic toggle="yes">HA-Slc4a11</italic>. <bold>A,</bold> Quantification of endothelial paracellular permeability with fluorescein dye. n = 3 animals (2 male and 1 female per group), Mean &#x000b1; SD. <bold>B,</bold> Quantification of mitochondrial ROS in the corneal endothelium using MitoSOX staining. n = 3 animals (1 male and 2 females per group). Mean &#x000b1; SD. <bold>C,</bold> Wes immunoassay of corneal endothelial peelings using superoxide dismutase 2 antibody. <bold>D,</bold> Quantification of Wes immunoassay results. When multiple bands were present, lower molecular weight band was used for quantification. n = 3 animals (1 male and 2 females per group for young and 2 females and 1 male per group for older animals), Mean &#x000b1; SD. ns = not significant, <italic toggle="yes">P</italic> &#x02265; 0.1 (1-way ANOVA with Tukey&#x02019;s multiple comparisons test). AAV9-HA = adeno-associated virus serotype 9 hemagglutinin.</p></caption><graphic xlink:href="nihms-1829272-f0007" position="float"/></fig></floats-group></article>
